Showing results (41-50 of 529) with videos related to

Sort By:
Pageof 53
European Heart Journal. Cardiovascular Pharmacotherapy|November 20, 2019
Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide studyAnne-Marie Schjerning Olsen, Patricia McGettigan, Thomas Alexander Gerds, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 6, 2019
Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trialAndré M Nicolau, Ramon Corbalan, Jose C Nicolau, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 27, 2019
Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trialMariusz Tomaniak, Ply Chichareon, Kuniaki Takahashi, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 25, 2019
An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcomeHeinz Drexel, Andrew J S Coats, Ilaria Spoletini, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 5, 2020
Aspirin-omitted dual antithrombotic therapy in non-valvular atrial fibrillation patients presenting with acute coronary syndrome or undergoing percutaneous coronary intervention: results of a meta-analysisCheng-Feng Luo, Pei Mo, Guo-Qiang Li, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 13, 2020
Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysisHannah Wilson, Declan Patton, Zena Moore, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 31, 2019
Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortalityJoris J Komen, Tomas Forslund, Aukje K Mantel-Teeuwisse, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 4, 2019
Meta-analysis of studies examining the external validity of the dual antiplatelet therapy scoreGuy Witberg, Oren Zusman, Dafna Yahav, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 17, 2020
Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort studyOle-Christian W Rutherford, Christian Jonasson, Waleed Ghanima, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 1, 2020
Thromboembolism and bleeding complications in anticoagulated patients with atrial fibrillation and native aortic or mitral valvular heart disease: a descriptive nationwide cohort studyLine Melgaard, Thure Filskov Overvad, Martin Jensen, et al.
Pageof 53